Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma

Introduction The ALCYONE trial found that daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) can significantly improve progression-free survival (PFS) and overall survival (OS) for patients with transplant-ineligible, newly diagnosed multiple myeloma (MM) in China. In the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Advances in therapy 2021-05, Vol.38 (5), p.2379-2390
Hauptverfasser:	Zeng, Xiaohui, Liu, Qiao, Peng, Liubao, Peng, Ye, Yi, Lidan, Luo, Xia, Li, Sini, Wan, Xiaomin, Tan, Chongqing
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Endocrinology Health technology assessment Internal Medicine Medicine Medicine & Public Health Oncology Original Research Pharmacology/Toxicology Rheumatology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!